Kisunla (donanemab)
Research Synopsis
- * Recent studies indicate donanemab has shown promise in reducing amyloid deposits in patients with Alzheimer's, with significant reductions observed in amyloid levels after administration.
- * The TRAILBLAZER-ALZ trial highlighted that donanemab was well tolerated at doses up to 10 mg/kg and resulted in a notable 40-50% reduction in amyloid levels at the highest doses despite some cases of asymptomatic brain swelling.
- * There is growing optimism in the scientific community regarding donanemab's potential, particularly in how it may address the challenges of AD treatment, but reports also caution about its limited effects on cognitive abilities and daily functioning.
- * Donanemab is currently being explored alongside other amyloid-targeting therapies such as aducanumab and lecanemab, amid calls for better-designed trials to enhance efficacy in AD treatments.
- * Research points out that while targeting amyloid plaques could be beneficial, there is a shift towards considering new strategies that also address neuroinflammatory markers and other pathological mechanisms underlying AD.
- * Concerns have been raised about potential side effects, including amyloid-related imaging abnormalities (ARIA), which necessitate careful management and monitoring in clinical settings.
- * Overall, while donanemab is part of a promising wave of Alzheimer’s therapies, experts advise that further understanding of its effects and mechanisms is needed, urging careful consideration of resources and research direction in the future.
- * The combination therapy potentials, such as pairing donanemab with other drugs targeting specific pathologies, are being investigated to maximize treatment efficacy.
- * As of October 2023, the ongoing developments and clinical trials of donanemab suggest a cautious optimism in its role within the Alzheimer's treatment landscape, highlighting the potential for tailored therapeutic strategies.
Kisunla (donanemab)
Can Targeted Protein Degradation Technology Provide a Potential Breakthrough in the Development of Anti-AD Drugs?
London, UK
2 hours ago
1 Received
- Scientists have made new discoveries about Alzheimer’s disease (AD) and found two treatments called lecanemab and donanemab that work well!
- Researchers are excited about tiny medicines that can break down amyloid-beta (Aβ), which could improve how we treat AD!
- Even though there are some challenges, these new treatments might be the future solution for Alzheimer’s, thanks to recent scientific progress!
$100 - $150
Hourly Rate
Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?
London, UK
2 hours ago
1 Received
- Recent drugs for Alzheimer's disease have not worked well and can cause serious problems.
- Scientists are looking at how inflammation in the brain might be linked to Alzheimer's and how it changes over time.
- New blood tests could help doctors understand Alzheimer's better and match treatments to individual patients based on their specific symptoms.
$100 - $150
Hourly Rate
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
London, UK
2 hours ago
1 Received
- The study evaluated the safety and tolerability of donanemab, a potential Alzheimer's treatment, in patients with mild cognitive impairment or mild to moderate dementia.
- Participants received varying single and multiple doses of donanemab, followed by monitoring periods to assess outcomes and safety.
- Results indicated that donanemab was well tolerated at doses up to 10 mg/kg and effectively reduced amyloid deposits, notably achieving a 40-50% reduction at the highest dose, despite a shorter half-life than anticipated.
$100 - $150
Hourly Rate
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Donanemab in Early Alzheimer's Disease.
London, UK
2 hours ago
1 Received
- Donanemab is an antibody designed to target amyloid-β (Aβ) peptide deposits, which are characteristic of Alzheimer's disease, and is being tested for early-stage treatment.
- A phase 2 trial involved 257 patients with early symptomatic Alzheimer's; they received either donanemab or a placebo for up to 72 weeks, with cognitive changes assessed primarily via the Integrated Alzheimer's Disease Rating Scale (iADRS).
- Results showed that donanemab had a slightly better effect on cognitive decline compared to placebo, with some reduction in amyloid levels, but no significant differences in most secondary cognitive measures and some cases of asymptomatic brain swelling were reported.
$100 - $150
Hourly Rate
Critical Appraisal of Amyloid Lowering Agents in AD.
London, UK
2 hours ago
1 Received
- The amyloid cascade hypothesis suggests that clearing amyloid beta (Aβ) could potentially cure Alzheimer's disease (AD), but previous treatments have shown limited success, prompting researchers to explore new therapeutic strategies like immunotherapy.
- Currently, several monoclonal antibody (mAb) therapies aimed at targeting and removing Aβ plaques are under development, including aducanumab, lecanemab, solanezumab, crenezumab, donanemab, and gantenerumab, which could be effective at various stages of AD.
- The FDA's upcoming decision on aducanumab is expected to significantly influence the future of mAb drug development for AD, and there's a call for improved trial designs to enhance treatment outcomes and
$100 - $150
Hourly Rate
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.
London, UK
2 hours ago
1 Received
- Research indicates that soluble beta amyloid oligomers are key contributors to the development of Alzheimer's disease (AD).
- Recent clinical trials suggest that targeting these oligomers, rather than just clearing amyloid plaques, is necessary for effective treatment of AD symptoms.
- Successful agents in these trials, including several antibodies and an oral medication, show that reducing Aβ neurotoxicity can also decrease tau pathology, linking the two processes in the progression of AD.
$100 - $150
Hourly Rate
Donanemab removes Alzheimer's plaques: what is special about its target?
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Donanemab in Early Alzheimer's Disease. Reply.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
N-Truncated Aβ Starting at Position Four-Biochemical Features, Preclinical Models, and Potential as Drug Target in Alzheimer's Disease.
London, UK
2 hours ago
1 Received
- There has been ongoing debate about whether amyloid plaque Aβ is a valid drug target for Alzheimer's disease (AD), which can only be resolved through effective clinical trials and new drug approvals.
- Many past clinical trials using antibodies targeting amyloid Aβ have failed to meet necessary clinical endpoints, but recent trials with Donanemab have shown some promise in patients, indicating N-truncated Aβ as a potential therapeutic target.
- This review aims to explore the role of Aβ, particularly N-truncated variants, in AD pathology and assesses their relevance as targets for drug development based on existing research in human and mouse models.
$100 - $150
Hourly Rate
Donanemab in Early Alzheimer's Disease.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Still grasping at straws: donanemab in Alzheimer's disease.
London, UK
2 hours ago
1 Received
- - Alzheimer's disease greatly affects both individuals and their caregivers, leading to emotional and financial burdens, while donanemab is a new treatment targeting a specific form of Amyloid-β associated with the disease.
- - In the phase 2 TRAILBLAZER-ALZ trial, donanemab was shown to decrease cerebral plaques but had limited impact on cognitive abilities and daily activities, indicating only marginal improvements.
- - Experts suggest that since donanemab did not significantly change tau load, and its effect on cognition remains unclear, resources should be redirected from current amyloid-targeting treatments to exploring the root causes of Alzheimer's disease instead.
$100 - $150
Hourly Rate
Brain volume loss due to donanemab.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice.
London, UK
2 hours ago
1 Received
- Pyroglutamate-modified Aβ (pGlu3-Aβ) peptides are linked to the onset and progression of Alzheimer's disease, leading to research on therapies targeting these peptides.
- Current clinical approaches include the use of Varoglutamstat (a glutaminyl cyclase inhibitor) and Donanemab (a monoclonal antibody) to combat pGlu3-Aβ peptides.
- In studies with transgenic mice, combining Varoglutamstat with a specific antibody showed significant reductions in Aβ levels, suggesting that the combo treatment could enhance effectiveness while allowing for lower doses of each drug.
$100 - $150
Hourly Rate
Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
London, UK
2 hours ago
1 Received
- Donanemab is an IgG1 antibody targeting a specific form of amyloid beta associated with Alzheimer's disease, and a clinical study aimed to evaluate its effects on reducing brain amyloid plaque levels after different dosing regimens.
- The study involved 61 participants with mild cognitive impairment or mild-to-moderate Alzheimer's, who received either single or multiple doses of donanemab or a placebo over a period of up to 72 weeks.
- Results indicated that donanemab significantly reduced amyloid plaques in the brain within 24 weeks, with greater reductions observed in patients receiving higher or more frequent doses compared to the placebo group.
$100 - $150
Hourly Rate
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Genomics of Alzheimer's disease implicates the innate and adaptive immune systems.
London, UK
2 hours ago
1 Received
- - Alzheimer's disease (AD) is a chronic condition marked by cognitive decline and behavioral changes, with genetic factors linked to over 130 susceptibility loci identified through genome-wide studies and sequencing techniques, highlighting the roles of several key genes like APOE and TREM2.
- - Aging is the primary risk factor for late-onset Alzheimer's, and research indicates that the accumulation of mutations affects cell-mediated clearance of amyloid-β (Aβ), contributing to the disease's development and progression, particularly through myeloid immune responses.
- - New treatment approaches, including passive immunization therapies like aducanumab and lecanemab, aim to enhance Aβ clearance and potentially slow cognitive decline, while boosting innate immune functions in myeloid cells
$100 - $150
Hourly Rate
Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.
London, UK
2 hours ago
1 Received
- The inhibition of glutaminyl cyclase (QC) is a potential strategy for early Alzheimer's disease treatment by lowering toxic forms of β-amyloid (Aβ) in the brain.
- Researchers identified strong QC inhibitors, with one compound (214) showing the highest potency in lab tests, while another (227) demonstrated impressive effectiveness in living organisms and improved behavior in mice.
- The study revealed a strong binding interaction between QC and compound 214, suggesting that QC inhibitors could be valuable additions to current treatments for early-stage Alzheimer's disease.
$100 - $150
Hourly Rate
Mini review: Prospective therapeutic targets of Alzheimer's disease.
London, UK
2 hours ago
1 Received
- Alzheimer's disease is a progressive neurological disorder affecting about 10% of people over 65 in the U.S., disrupting brain connections and currently lacking a cure.
- While physicians can treat symptoms, they cannot halt the disease's progression; however, recent research shows promising therapeutic targets from studies on mice.
- Key targets include meningeal lymphatics, mitochondrial and calcium homeostasis, genomic instability, and specific cold-shock proteins, which may lead to potential treatments in the future.
$100 - $150
Hourly Rate
Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.
London, UK
2 hours ago
1 Received
- * These treatments can cause a significant side effect known as amyloid-related imaging abnormality (ARIA), which is detectable on MRI and can lead to symptoms like headaches, confusion, and even serious conditions such as seizures or bleeding.
- * Management of ARIA may involve regular MRI monitoring and adjusting dosages, and while some anecdotal evidence suggests that corticosteroids or anticonvulsants might help, more controlled studies are needed to verify effective prevention and treatment strategies.
$100 - $150
Hourly Rate